European Union - English - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - lutetium (177lu) chloride, quantity: 10 gbq/ml - solution - excipient ingredients: dilute hydrochloric acid; purified water - lutetium (177lu) chloride is a radiopharmaceutical precursor, and it is not intended for direct use in patients. for the treatment of non resectable or metastatic neuroendocrine tumours (nets) expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.

United States - English - NLM (National Library of Medicine)

advanced accelerator applications usa, inc - lutetium oxodotreotide lu-177 (unii: ae221im3bb) (lutetium oxodotreotide lu-177 - unii:ae221im3bb) - lutetium oxodotreotide lu-177 10 mci in 1 ml - lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (gep-nets), including foregut, midgut, and hindgut neuroendocrine tumors in adults. none. risk summary based on its mechanism of action, lutathera can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on lutathera use in pregnant women. no animal studies using lutetium lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from lutathera, can cause fetal harm. advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data on the presence of lutetium lu 177 dotatate in human milk, or its effects on the breastfed child or

Australia - English - Department of Health (Therapeutic Goods Administration)

tongxin natural products pty ltd - lutein, quantity: 9 mg - capsule, soft - excipient ingredients: soya oil; gelatin - improves the health of the macular region of the eye. supplements containint natural lutein esters have been shown to increase macular pigment density. high amounts of lutein and zeaxanthin in the retina, higher macular pigment density is associated with healthier eyes and the retention of visual sensitivity. may improve visual acuity/sharpness. lutein and zeaxanthin and food rich in these carotenoids may improve the health of the lens. lutein and zeaxanthin provide antioxidant functions in maintaining eye health. may help defend against and/or reduce the risk of age-related damage to the macula. may help defend against the risk of age-related disease of the macula.

Australia - English - Department of Health (Therapeutic Goods Administration)

d & x pty ltd - lutein,zeaxanthin -

European Union - English - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - endolucinbeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Australia - English - Department of Health (Therapeutic Goods Administration)

proudex australia pty ltd - lutein, quantity: 20 mg; betacarotene, quantity: 3 mg; vaccinium myrtillus, quantity: 100 mg (equivalent: vaccinium myrtillus, qty 10 g; equivalent: anthocyanosides (of vaccinium myrtillus), qty 25 mg); vitis vinifera, quantity: 16.7 mg (equivalent: vitis vinifera, qty 2.004 g; equivalent: procyanidins (of vitis vinifera), qty 15.9 mg); linseed oil, quantity: 800 mg (equivalent: oleic acid, qty 120 mg; equivalent: linoleic acid, qty 120 mg; equivalent: linolenic acid, qty 440 mg) - capsule, soft - excipient ingredients: maize oil; white beeswax; d-alpha-tocopherol; lecithin; glycerol; iron oxide red; purified water; titanium dioxide; soya oil; iron oxide black; hydrogenated vegetable oil; gelatin - antioxidant/reduce free radicals formed in the body ; maintain/support healthy eye function ; maintain/support eye health ; helps maintain/support eye macula health ; decrease/reduce/relieve eye strain ; maintain/support healthy eyesight/vision ; maintain/support skin health

Israel - English - Ministry of Health

novartis israel ltd - lutetium (177lu) vipivotide tetraxetan - solution for injection / infusion - lutetium (177lu) vipivotide tetraxetan 1000 mbq/ml - lutetium (177lu) vipivotide tetraxetan - pluvicto is indicated for the treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.

United States - English - NLM (National Library of Medicine)

hahnemann laboratories, inc. - lutetium (unii: 5h0doz21uj) (lutetium - unii:5h0doz21uj) -

Australia - English - Department of Health (Therapeutic Goods Administration)

australian natural health pharmaceuticals pty ltd - lutein, quantity: 3 mg; vaccinium myrtillus, quantity: 100 mg (equivalent: vaccinium myrtillus, qty 10 g); zeaxanthin, quantity: 195 microgram - capsule, soft - excipient ingredients: lecithin; iron oxide red; titanium dioxide; hydrogenated vegetable oil; soya oil; glycerol; yellow beeswax; iron oxide black; iron oxide yellow; vegetable oil; purified water; d-alpha-tocopherol; gelatin - maintain/support healthy eye function ; maintain/support eye health ; maintain/support general health and wellbeing